LifeSpan Vision Ventures invests in Matter Bio

2023-10-24 00:43:05

Norwalk, Conn. (ots/PRNewswire) – LifeSpan Vision Ventures today announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. At the heart of the company’s philosophy is the recognition that our genome is constantly damaged by exogenous and endogenous sources as we age. Occasionally, errors are overlooked and incorporated into DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. Matter Bio has assembled a world-class team of scientists and leaders to address this critical loss of information in the genome. To achieve this, the company has adopted a hub-and-spoke model to advance multiple scientific breakthroughs, each addressing critical points of information loss. To date, Matter Bio has three companies under its management, with others in the incubation phase.

“Matter Bio continues to advance its commercial, clinical and research programs, and the proceeds from Lifespan Vision Venture’s investment will support the advancement of the company’s portfolio toward key scientific and commercial milestones,” said Chris Bradley, CEO of Matter Bio.

Matter Bio expects to begin clinical trials for one of its programs in the next 12 months, as well as expand an already high-volume program in single-molecule mutation sequencing.

Dr. med. Jordan B. Burton, scientific analyst at LifeSpan Vision Ventures, stated: “Our investment in Matter Bio underscores our mission to support companies dedicated to longevity and slowing the key drivers of aging. The company’s business model combines academic expertise, efficiency and scalability to pursue the mission of quantifying and reversing DNA damage to prevent diseases of aging and extend healthy lifespans. We are excited to work with such a talented team of pioneers in genomics and look forward to seeing how the company can extend health and address the critical loss of information in the genome.”

Information about Matter Bio Matter Bio was developed alongside world-class scientists such as George Church PhD. and Jan Vijg PhD. and is a holding company that advances multiple scientific breakthroughs, each targeting a critical point of information loss. The company’s core competencies include accurate sequencing of mutations, reversal of somatic mutations and elimination of pathological cells, including cancer.

Further information can be found at https://matterbio.com/.

About LifeSpan Vision Ventures LifeSpan Vision Ventures is a forward-thinking venture capital firm specializing in aging and longevity investments. Our goal is to support and accelerate the development of innovative therapies that extend life expectancy, improve quality of life in old age and address age-related challenges. Through strategic partnerships and investments, we aim to shape a future where aging is accompanied by vitality, resilience and endless possibilities.

For more information about LifeSpan Vision Ventures, visit https://www.lifespanvisionventures.com/.

harry.robb@lifespanvision.com